Blueprint Medicines has identified new cAMP-dependent protein kinase catalytic subunit alpha (PRKACA) inhibitors reported to be useful for the treatment of Carney complex (NAME syndrome, LAMB syndrome), McCune-Albright syndrome, polycystic kidney disease and cancer.

TFChem SAS has described new cyclic glycoaminoacid derivatives reported to be useful for the treatment of dry skin, atopic dermatitis, aging, inflammatory disorders, fibrosis and psoriasis, among other disorders.

Allorion Therapeutics has divulged imidazolopyridazines or pyrazolopyrimidines acting as nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.

Lynk Pharmaceuticals' LNK-01004 has been cleared by China's National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis.